- Home
- ICCC vs RAND Comparison
ICCC vs RAND Comparison
Compare ICCC & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- RAND
- Stock Information
- Founded
- ICCC 1982
- RAND 1969
- Country
- ICCC United States
- RAND United States
- Employees
- ICCC N/A
- RAND N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- RAND Finance: Consumer Services
- Sector
- ICCC Health Care
- RAND Finance
- Exchange
- ICCC Nasdaq
- RAND Nasdaq
- Market Cap
- ICCC 60.1M
- RAND 57.6M
- IPO Year
- ICCC 1987
- RAND N/A
- Fundamental
- Price
- ICCC $6.98
- RAND $16.14
- Analyst Decision
- ICCC
- RAND
- Analyst Count
- ICCC 0
- RAND 0
- Target Price
- ICCC N/A
- RAND N/A
- AVG Volume (30 Days)
- ICCC 44.4K
- RAND 5.4K
- Earning Date
- ICCC 08-12-2025
- RAND 08-05-2025
- Dividend Yield
- ICCC N/A
- RAND 10.54%
- EPS Growth
- ICCC N/A
- RAND 39.77
- EPS
- ICCC N/A
- RAND 3.12
- Revenue
- ICCC $27,302,766.00
- RAND $8,499,970.00
- Revenue This Year
- ICCC N/A
- RAND N/A
- Revenue Next Year
- ICCC N/A
- RAND N/A
- P/E Ratio
- ICCC N/A
- RAND $4.97
- Revenue Growth
- ICCC 28.29
- RAND 12.52
- 52 Week Low
- ICCC $3.34
- RAND $14.01
- 52 Week High
- ICCC $7.60
- RAND $31.89
- Technical
- Relative Strength Index (RSI)
- ICCC 55.17
- RAND 41.37
- Support Level
- ICCC $5.63
- RAND $15.30
- Resistance Level
- ICCC $7.55
- RAND $15.89
- Average True Range (ATR)
- ICCC 0.54
- RAND 0.30
- MACD
- ICCC -0.03
- RAND 0.12
- Stochastic Oscillator
- ICCC 61.24
- RAND 43.62
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.